证券代码：688603 证券简称：天承科技 公告编号：2025-028 广东天承科技股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 公司存在首发战略配售股份，首发战略配售股份未全部上市流通 ? 是否涉及差异化分红送转：是 ? 每股分配比例，每股转增比例 每股现金红利0.3元（含税） 每股转增0.49股 ? 相关日期 新增无限售条件流通 股权登记日 除权（息）日 现金红利发放日 股份上市日 一、通过分配、转增股本方案的股东会届次和日期 本次利润分配及转增股本方案经公司2025 年 4 月 30 日的2024年年度股东会审 议通过。 二、分配、转增股本方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部 ...

差异化权益分派事项的核查意见 民生证券股份有限公司（以下简称"保荐机构"或"民生证券"）作为广东 天承科技股份有限公司（以下简称"公司"或"天承科技"）首次公开发行股票 并在科创板上市的保荐机构，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司股份回购规则》、《上海证券交易所上市公司自律监管 指引第 7 号——回购股份》等相关法律法规的规定，对天承科技 2024 年度利润 分配所涉及的差异化权益分派事项（以下简称"本次差异化权益分派"）进行了 核查，核查具体情况如下： 一、本次差异化权益分派的原因 2024 年 1 月 31 日，公司召开第二届董事会第六次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞价交易方式 回购公司股份，并在未来适宜时机全部用于员工持股计划或股权激励。回购股份 的资金总额不低于人民币 3,000 万元（含），不高于人民币 5,000 万元（含）； 资金来源为自有资金；回购的价格不超过人民币 75 元/股；回购的期限为自公司 董事会审议通过本次回购方案之日起 12 个月内。上述回购方案已于 2025 年 1 月 27 日实施完毕。 ...

证券代码：688603 证券简称：天承科技 公告编号：2025-028 广东天承科技股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流通 | 现金红利发放日 | | --- | --- | --- | --- | | | | 股份上市日 | | | 2025/6/12 | 2025/6/13 | 2025/6/13 | 2025/6/13 | 一、通过分配、转增股本方案的股东会届次和日期 本次利润分配及转增股本方案经公司2025 年 4 月 30 日的2024年年度股东会审 议通过。 二、分配、转增股本方案 1、发放年度：2024年年度 2、分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引 ...

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

近日，广东天承科技股份有限公司（以下简称"公司"或"天承科技"）全 资子公司广东天承化学有限公司（以下简称"天承化学"）收到珠海市自然资源 局出具的《征缴土地闲置费决定书》（珠自然资金闲置征决[2025]002 号）（以下 简称"《决定书》"），现将有关情况公告如下： 一、《决定书》主要内容及公司缴费情况 证券代码：688603 证券简称：天承科技 公告编号：2025-027 广东天承科技股份有限公司 关于全资子公司收到《征缴土地闲置费决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《珠海市闲置土地处置实施细则》第二十二条第（一）项、第二十四 条的规定，珠海市自然资源局决定对天承化学名下一宗闲置土地按照国有建设 用地使用权人实际应缴土地价款本金（不包含滞纳金及利息）总额的百分之二 十征缴土地闲置费，土地闲置费数额为 216.5782 万元。自决定书送达之日起 30 日内到税务部门办理土地闲置费缴纳手续。 该闲置土地为工业用地，土地证号：粤（2022）珠海市不动产第 0401061 号，位于珠海经济技术开 ...

Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by a significant shareholder, Rui Xing Phase II, due to personal funding needs, which may impact the company's stock performance and investor sentiment [1][4]. Shareholder Information - Rui Xing Phase II directly holds 2,533,542 shares, representing 3.0177% of the total share capital of the company [1]. - The shareholder is not a controlling shareholder or a major stakeholder [1]. Reduction Plan Details - The reduction plan is set to occur from May 23, 2025, to August 20, 2025, with a maximum reduction of 2,518,714 shares, not exceeding 3% of the total share capital [2][3]. - The reduction will be executed through centralized bidding and block trading, with up to 839,571 shares through centralized bidding and 1,679,143 shares through block trading [2]. Reason for Reduction - The primary reason for the share reduction is the shareholder's personal funding needs [4]. Compliance and Commitments - Rui Xing Phase II has made commitments regarding the reduction, including prior announcements three trading days before any share reduction and adherence to relevant regulations [4][5]. - The company confirms that the reduction plan aligns with previously disclosed commitments and will not lead to a change in control [5].

证券代码：688603 证券简称：天承科技 公告编号：2025-026 广东天承科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东的基本情况 截至本公告披露日，宁波市睿兴二期股权投资合伙企业（有限合伙）（以下 简称"睿兴二期"）直接持有公司股份 2,533,542 股，占总股本的 3.0177%。 减持计划的主要内容 公司于 2025 年 5 月 16 日收到股东睿兴二期发来的《关于股东减持计划的告 知函》,因股东自身资金需求，睿兴二期计划自 2025 年 5 月 23 日至 2025 年 8 月 20 日期间，通过大宗交易和集中竞价的方式合计减持公司股份不超过 2,518,714 股，合计减持股份占公司总股本的比例不超过 3%。 | 股东名称 | 睿兴二期 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | ...

Core Viewpoint - Tiancheng Technology (688603.SH) has faced delays in its fundraising projects, with significant implications for its operational strategy and future growth [1][2]. Group 1: Financial Performance and Fundraising - Tiancheng Technology disclosed a total investment of 112.61 million yuan in fundraising by the end of 2024, with a cumulative investment progress of 15.92% [1]. - The company raised a total of 799.38 million yuan through its IPO, with a net amount of 707.38 million yuan after deducting issuance costs, which was 306.29 million yuan more than originally planned [2]. - The IPO was conducted at a price of 55.00 yuan per share, with 14.53 million shares issued, representing 25% of the total share capital post-issuance [2]. Group 2: Project Development and Delays - The "Annual Production of 30,000 Tons of Special Electronic Materials and Electronic Chemicals Project" and the "Zhuhai R&D Center Construction Project" both have a progress rate of 0%, with completion dates postponed to April 2027 [1]. - The slow progress of the projects is attributed to the company's strategy of unified project planning and design, which requires land acquisition for the Zhuhai R&D Center, which has been delayed due to policy changes [1]. - The company aims to improve the efficiency of fundraising usage and avoid resource duplication, leading to the decision to synchronize the development of related projects [1]. Group 3: Strategic Partnerships - Minsheng Securities Investment Co., a subsidiary of the lead underwriter, participated in a strategic allocation, acquiring 726,711 shares, which is 5% of the total issuance, with an investment amount of approximately 39.97 million yuan [3]. - The shares acquired by Minsheng Investment are subject to a holding period of 24 months from the date of the IPO [3].

Dividend and Share Capital - The company plans to distribute a cash dividend of 3 CNY per 10 shares, totaling 24,959,591 CNY, which represents 84.00% of the net profit attributable to shareholders for the year [6]. - The company intends to increase its capital reserve by issuing 4.9 new shares for every 10 shares held, resulting in a total of 40,767,332 new shares, increasing total shares to 124,724,524 [7]. - The total amount of cash dividends and share repurchases combined is 62,732,713.82 RMB, which represents 84.00% of the net profit attributable to shareholders for the year [196]. - The cash dividend amount accounts for 33.42% of the net profit attributable to shareholders, which is 74,679,913.48 RMB [200]. Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching $1.2 billion in Q3 2023 [15]. - The company's revenue for 2024 reached ¥380,670,972.91, representing a 12.32% increase compared to ¥338,928,877.29 in 2023 [27]. - The net profit attributable to shareholders for 2024 is CNY 74,679,913.48, an increase of 27.50% compared to the same period last year [28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 62,111,324.27, up 13.16% year-on-year [28]. - The net cash flow from operating activities for 2024 is CNY 71,096,999.52, reflecting a 14.37% increase from the previous year [30]. - The company's operating revenue for the current period is CNY 380,670,972.91, representing a 12.32% increase compared to CNY 338,928,877.29 in the same period last year [106]. - Operating costs increased by 5.07% to CNY 228,957,065.57 from CNY 217,915,269.81 year-on-year [106]. - The gross profit margin for the main business increased by 4.17 percentage points to 39.76% [110]. Research and Development - The company is investing $200 million in R&D for advanced packaging technologies, aiming to enhance product performance [15]. - The R&D expenditure as a percentage of operating revenue is 7.35%, an increase of 0.75 percentage points from 6.60% in 2023 [29]. - The total R&D investment for the year was approximately ¥27,968,219, an increase of 25.03% compared to the previous year [85]. - The company has increased its R&D personnel from 48 to 58, representing 25.66% of the total workforce [93]. - The company is focusing on developing high-end products to break the monopoly of foreign companies and fill domestic technology gaps [76]. - The company has established multiple core technologies related to PCB, chip packaging materials, and touch screens, maintaining strong core competitiveness [77]. Market Expansion and Strategy - The company plans to enter the European market by Q2 2024, targeting a revenue contribution of $100 million in the first year [15]. - Market expansion efforts have led to a 20% increase in market share in the Asia-Pacific region [16]. - The company is focusing on the development of functional wet electronic chemicals for semiconductor and photovoltaic applications [160]. - The company aims to enhance its market share in high-end printed circuit board products, particularly in copper plating and electroplating applications [160]. - The company is actively exploring new strategies to improve operational efficiency and reduce costs [17]. Corporate Governance - The company has received a standard unqualified audit report from Beijing Dehao International Accounting Firm [5]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance [5]. - The company has not reported any violations of decision-making procedures regarding external guarantees [10]. - The company has not indicated any special arrangements in corporate governance [8]. - The management emphasized the importance of maintaining high-quality standards in production processes to meet customer demands [17]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section, advising investors to be cautious [4]. - The company faces risks from intensified market competition and fluctuations in raw material prices, which could adversely affect its operating performance [101]. - The company recognizes the risk of foreign competitors dominating the high-end market due to their brand, capital, and technological advantages [102]. Employee and Management Structure - The company has a total of 226 employees, with 32 in the parent company and 194 in major subsidiaries [190]. - The employee composition includes 38 production personnel, 17 sales personnel, 67 technical personnel, 11 financial personnel, 35 administrative personnel, and 58 research and development personnel [190]. - The company established a competitive and performance-oriented compensation system, linking personal income to performance and contributions [192]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to RMB 5.9527 million [177]. Product Development and Innovation - The company has developed advanced semiconductor electroplating copper products with excellent filling capabilities and fine line capabilities [80]. - The company has made significant advancements in micro-etching technology, improving the stability of the etching rate and reducing overall production costs [80]. - The company is actively expanding its product offerings in semiconductor advanced packaging, focusing on key technologies and materials to support the growing demand for high-performance computing [58]. - The company has developed silicon via TSV electroplating additives that meet international standards, focusing on providing advanced solutions for leading customers [61]. Financial Management - The company has improved cash management strategies, leading to enhanced efficiency in fund utilization [28]. - The company experienced a substantial reduction in net cash flow from financing activities, decreasing by 109.85% to CNY -69,771,627.01 from CNY 708,314,039.20 in the previous year [107]. - The company's cash and cash equivalents decreased by 26.60% to ¥176,566,909.98 from ¥240,551,420.33 due to increased investments in financial products [126].

Core Viewpoint - Tiancheng Technology has reported that the progress of its two IPO fundraising projects, namely the "Annual Production of 30,000 Tons of Special Electronic Materials Chemical Products Project" and the "Zhuhai R&D Center Construction Project," is currently at 0% due to the lack of land use rights for the Zhuhai project [1][5]. Group 1: Project Progress - As of the end of last year, both the "Annual Production of 30,000 Tons of Special Electronic Materials Chemical Products Project" and the "Zhuhai R&D Center Construction Project" have not commenced construction [2][5]. - The company stated that the slow progress of the Zhuhai R&D Center is primarily due to policy adjustments that have delayed the acquisition of necessary land use rights [5]. Group 2: Financial Performance - Since its listing in July 2023, the company has experienced continuous growth in sales revenue and profits, indicating that the development of its main business does not currently rely on the implementation of the fundraising projects [5]. Group 3: Inventory Management - As of the end of 2024, the company's issued goods account balance is approximately 25.88 million yuan, accounting for 64.83% of the total inventory balance [6]. - The company explained that the issued goods are primarily products sent to customers based on their expected consumption, which have not yet met the revenue recognition criteria due to not being signed for by the customers [9].